Oncopeptides (ONCO)

Executive Summary

Oncopeptides AB is a Swedish biotech company focused on developing targeted therapies for hematological cancers and solid tumors. Its lead asset, Pepaxti (melphalan flufenamide), is approved in the US for relapsed/refractory multiple myeloma but has faced commercial challenges due to safety concerns and competition. The company is evaluating Pepaxti in combination regimens and earlier lines of therapy to expand its addressable market. Additionally, Oncopeptides has a preclinical pipeline of peptide-drug conjugates targeting solid tumors. The company's small market cap (~$4.3M) reflects limited near-term revenue and high risk, but its novel technology platform could offer upside if clinical data show improved efficacy and safety. Financial discipline and potential partnerships are key to extending cash runway.

Upcoming Catalysts (preview)

• Q3 2026Pepaxti combination trial data in multiple myeloma30% success
• TBDRegulatory update for Pepaxti in EU25% success
• TBDPartnership or licensing deal for pipeline assets20% success